SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001561743-20-000007
Filing Date
2020-03-16
Accepted
2020-03-16 16:08:49
Documents
6
Period of Report
2020-03-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8k-march162020.htm 8-K 43152
2 EXHIBIT 2.1 exhibit21-assetpurchaseagr.htm EX-2.1 377262
3 EXHIBIT 10.1 exhibit101-firstamendmentt.htm EX-10.1 140808
4 EXHIBIT 99.1 a2019q4earningsrelease.htm EX-99.1 50236
5 prfin1.jpg GRAPHIC 67250
6 prfin2.jpg GRAPHIC 22516
  Complete submission text file 0001561743-20-000007.txt   725721
Mailing Address 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Business Address 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 650-701-7901
Kindred Biosciences, Inc. (Filer) CIK: 0001561743 (see all company filings)

IRS No.: 461160142 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36225 | Film No.: 20717190
SIC: 2834 Pharmaceutical Preparations